Werlabs stock

About Werlabs Operations

Werlabs is a Swedish medical technology company that provides digital health checkups based on blood tests, blood pressure readings and lifestyle data. The service targets both private individuals and corporate customers who want to monitor and understand their health status over time in a structured and accessible way.

Customers order health check packages online, select a sampling location from a nationwide network and complete venous blood sampling on site. The samples are analysed by external accredited laboratories in Sweden, and the results are reviewed and commented on by licensed physicians engaged by Werlabs.

By combining laboratory data with information on lifestyle and medical history, Werlabs aims to support more preventive and data driven healthcare behaviour. The company acts as a complement to the public healthcare system, offering self-initiated tests where the customer decides the scope and focus of the checkup.

Werlabs Business Model

Werlabs generates revenue primarily through the sale of health check packages and specific blood tests to private customers and employers. Each package is priced as a fixed fee that includes sampling, laboratory analysis and a written medical comment from a physician. Orders and payments are handled through the company’s digital platform, which streamlines administration and supports scalability.

The company collaborates with independent laboratory partners for test analysis, allowing Werlabs to focus on digital infrastructure, product design, customer experience and medical assessment rather than running its own laboratories. The model is based on standardised test panels that can be combined with more targeted analyses when clinically relevant or requested by the customer.

In addition to serving consumers directly, Werlabs offers health programs for employers that want to follow and support employee health through structured screening initiatives. Corporate clients can sign agreements for recurring testing, which creates more predictable revenue and deeper relationships over time while giving employees access to a unified digital experience.

Growth and Development

Since its launch in 2013, Werlabs has built a sizeable user base consisting of several hundred thousand private customers and a growing number of corporate and organisational clients. Over time the company has broadened its offering with additional test panels, more sampling locations and a refined digital user interface, aiming to increase accessibility and ease of use for different customer segments.

A key element in Werlabs development is the ability to use collected data in a secure and responsible way, within applicable regulatory frameworks, to improve interpretation, follow up and recommendations. Tracking biomarkers over time enables more relevant insights into changes in individual health profiles and supports customers who choose to repeat testing at regular intervals.

The company operates in a market where awareness of preventive health, lifestyle related disease risk and personal health data has been increasing for several years. Within this context Werlabs has established a recognised brand and a partner network that provide a platform for continued growth, both by deepening penetration in the Swedish market and by broadening the range of use cases and customer groups it serves.

Market and Competition

Werlabs operates in the Swedish market for digital health services and laboratory based health checkups. Market development is influenced by demographic trends, an ageing population, growing interest in lifestyle related health, as well as continued digitalisation of healthcare services. At the same time, regulation, data protection requirements and the role of public healthcare shape the framework within which private providers can operate.

The competitive landscape includes traditional healthcare providers, private clinics and laboratory services, together with newer digital players offering direct to consumer testing and online consultations. Werlabs competes through a broad and structured portfolio of health check packages, a large network of sampling locations across Sweden and an integrated digital journey for ordering, sampling coordination, results presentation and follow up.

The relationship to public healthcare is both complementary and interlinked. Customers frequently use Werlabs results as input when engaging with primary care or specialist providers, which places requirements on medical quality, documentation and alignment with prevailing clinical practice. The company therefore needs to maintain close attention to guidelines and regulatory expectations in Sweden.

Technology and Differentiation

Werlabs core asset is a digital platform that connects customers, sampling sites, laboratories and physicians in a single workflow. The platform manages ordering, secure identification, payment, referrals, test results and doctor statements, and gives customers access to a personal online health journal where they can follow their markers over time.

All venous blood samples are analysed by accredited laboratory partners such as Karolinska Universitetslaboratoriet, Synlab and Unilabs, which contributes to analytical quality and reliability. By integrating laboratory data with its own interfaces for doctors and patients, Werlabs can deliver structured comments and visualisations that make complex biomarker information easier to interpret.

The company’s differentiation lies in the combination of digital accessibility, medical competence and a modular portfolio of standardised and targeted tests. The platform is designed to make the process predictable for the customer and to support physicians in providing consistent, well documented assessments, while keeping the underlying infrastructure flexible enough to add new panels and features when clinically and commercially justified.

Ownership and Capital Structure

Werlabs AB is a Swedish limited liability company registered in 2015 with its main operations in Sweden. Since inception the company has raised external capital to fund product development, technology, recruitment and market expansion, alongside capital provided by the founders. The shareholder base includes founders and professional investors with backgrounds in technology, healthcare and growth investing.

Historically, capital has been allocated to build and maintain the digital platform, expand the roster of physicians, secure long term laboratory partnerships and establish a broad network of sampling locations. As the company matures, focus shifts gradually towards efficiency, data driven optimisation of the offering and disciplined evaluation of new initiatives in relation to customer demand and regulatory conditions.

Ahead of any potential future listing, a clear capital allocation framework and governance structure is important, balancing continued product investment, commercial growth and financial resilience. For prospective investors Werlabs offers exposure to a regulated but growing market for digital health services, with an established operational platform and a business model built around recurring use and long term customer relationships.